(Check out Carter’s worthcharting.com for actionable recommendations and live nightly videos.) Mid-cap biotech Immunovant is judged to be setup especially well for a move higher, by our work. In the throes of a “bearish-to-bullish” reversal, the stock exhibits bullish price-volume correlation and impressive relative strength to the market and to other biotechnology stocks. We’re buyers here. Price Objective: $40+/- This pair of identical charts of Immunovant tell the story: Source: FactSet DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, or its parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL’S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
Trending
- Columbia University Considers $485 Million Bond Sale for May
- Prices pressured by Fed uncertainty, oil, and AI slowdown
- Mapletree Pan Asia Commercial Trust Posts Loss In Q4
- Stake and ACE & Company Partner to Launch Secondary Market for UAE Fractional Real Estate
- California is one step closer to America’s first billionaire wealth tax — and the divide between red and blue state taxes is getting deeper
- Deutsche Boerse Confirms 2026 Guidance
- Goldman raises oil price forecasts as Iran war deadlock continues; Shell buying Canada’s ARC in $13.6bn deal – business live | Business
- America’s Cultivation Corridor announces Cultivate 360 participants
Tuesday, April 28
